Moreover, given that a pharmacological inhibition of c-MYC is difficult (156), inhibition of DDX3X or DDX3Y could represent alternative therapeutic avenues for the treatment B-cell lymphoma in male patients with DDX3X LOF mutations (Figure 7). Here, DDX3Y is linked to B-cell non-Hodgkin lymphoma.